drugset / Trial / NCT07059091
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Phase 2
Recruiting
334 enrolled
Johns Hopkins University
American Lung Association · collabAmerican Lung Association Asthma Clinical Research Centers · collabGenentech, Inc. · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Timeline
- Start
- 2026-02-12
- Primary completion
- 2031-01
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omalizumab | Monoclonal antibody | — | Subcutaneous |